Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperkalemia | 14 | 2023 | 79 | 7.100 |
Why?
|
| Emergency Service, Hospital | 10 | 2023 | 1148 | 1.420 |
Why?
|
| Polymers | 3 | 2019 | 223 | 1.330 |
Why?
|
| Potassium | 7 | 2022 | 329 | 1.310 |
Why?
|
| Heart Failure | 8 | 2023 | 2516 | 1.250 |
Why?
|
| Emergency Medical Services | 6 | 2023 | 429 | 1.240 |
Why?
|
| Heart Arrest | 5 | 2023 | 358 | 0.940 |
Why?
|
| Silicates | 3 | 2020 | 11 | 0.880 |
Why?
|
| Personal Protective Equipment | 2 | 2022 | 64 | 0.820 |
Why?
|
| Atrial Flutter | 1 | 2021 | 21 | 0.820 |
Why?
|
| Pulmonary Edema | 1 | 2022 | 80 | 0.820 |
Why?
|
| Heart Injuries | 1 | 2021 | 40 | 0.810 |
Why?
|
| Cardiopulmonary Resuscitation | 5 | 2023 | 318 | 0.780 |
Why?
|
| Airway Management | 2 | 2022 | 102 | 0.770 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 115 | 0.750 |
Why?
|
| Electrocardiography | 4 | 2023 | 1145 | 0.710 |
Why?
|
| Infection Control | 1 | 2021 | 270 | 0.690 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 130 | 0.680 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 259 | 0.650 |
Why?
|
| Pain | 3 | 2022 | 1658 | 0.620 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 342 | 0.600 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 75 | 0.600 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 960 | 0.590 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 719 | 0.480 |
Why?
|
| Hypokalemia | 1 | 2014 | 55 | 0.480 |
Why?
|
| Fever | 1 | 2015 | 497 | 0.430 |
Why?
|
| Ischemia | 1 | 2015 | 391 | 0.420 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 521 | 0.420 |
Why?
|
| Humans | 50 | 2024 | 261506 | 0.400 |
Why?
|
| Patient Discharge | 4 | 2023 | 661 | 0.390 |
Why?
|
| Albuterol | 2 | 2023 | 76 | 0.390 |
Why?
|
| Insulin | 4 | 2023 | 1454 | 0.390 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2023 | 89 | 0.380 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 335 | 0.380 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 915 | 0.370 |
Why?
|
| Vitamin D | 2 | 2021 | 261 | 0.340 |
Why?
|
| Sufentanil | 2 | 2019 | 8 | 0.340 |
Why?
|
| Ketamine | 2 | 2023 | 234 | 0.340 |
Why?
|
| Acute Pain | 2 | 2019 | 42 | 0.320 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 1371 | 0.320 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 787 | 0.320 |
Why?
|
| Acute Disease | 3 | 2023 | 2422 | 0.310 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 444 | 0.310 |
Why?
|
| Pilot Projects | 3 | 2022 | 2803 | 0.270 |
Why?
|
| Pain Management | 4 | 2022 | 668 | 0.260 |
Why?
|
| Aftercare | 2 | 2023 | 259 | 0.250 |
Why?
|
| Microfluidics | 1 | 2024 | 33 | 0.240 |
Why?
|
| Adult | 13 | 2024 | 77950 | 0.240 |
Why?
|
| Vitamins | 2 | 2021 | 157 | 0.240 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2023 | 5 | 0.230 |
Why?
|
| Hospitals | 3 | 2023 | 485 | 0.230 |
Why?
|
| Renal Dialysis | 2 | 2022 | 945 | 0.230 |
Why?
|
| Ethics Committees, Research | 1 | 2023 | 40 | 0.230 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 107 | 0.220 |
Why?
|
| Prospective Studies | 5 | 2022 | 12873 | 0.220 |
Why?
|
| Hematology | 1 | 2024 | 104 | 0.220 |
Why?
|
| Milrinone | 1 | 2022 | 33 | 0.210 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 103 | 0.210 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 92 | 0.210 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 1374 | 0.210 |
Why?
|
| Analgesia | 1 | 2022 | 94 | 0.200 |
Why?
|
| Status Epilepticus | 1 | 2023 | 145 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 543 | 0.200 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 73 | 0.190 |
Why?
|
| Airway Extubation | 1 | 2021 | 65 | 0.190 |
Why?
|
| Dietary Supplements | 2 | 2022 | 558 | 0.190 |
Why?
|
| Laryngoscopes | 1 | 2022 | 86 | 0.180 |
Why?
|
| Medication Systems, Hospital | 1 | 2019 | 38 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2021 | 108 | 0.180 |
Why?
|
| Calcitonin | 1 | 2020 | 186 | 0.180 |
Why?
|
| Myocarditis | 1 | 2021 | 190 | 0.170 |
Why?
|
| Sodium Bicarbonate | 1 | 2019 | 59 | 0.170 |
Why?
|
| Protein Precursors | 1 | 2020 | 240 | 0.170 |
Why?
|
| Dyspnea | 1 | 2022 | 416 | 0.170 |
Why?
|
| Pain Measurement | 3 | 2019 | 953 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2021 | 292 | 0.170 |
Why?
|
| Hospitalization | 3 | 2023 | 2083 | 0.160 |
Why?
|
| Codeine | 1 | 2018 | 21 | 0.160 |
Why?
|
| Diuretics | 1 | 2019 | 170 | 0.160 |
Why?
|
| Female | 13 | 2023 | 141928 | 0.160 |
Why?
|
| Hydrocodone | 1 | 2018 | 55 | 0.160 |
Why?
|
| Male | 12 | 2023 | 123000 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2594 | 0.150 |
Why?
|
| Influenza B virus | 1 | 2018 | 127 | 0.150 |
Why?
|
| Potassium, Dietary | 1 | 2017 | 12 | 0.150 |
Why?
|
| Calcium Gluconate | 1 | 2017 | 7 | 0.150 |
Why?
|
| Professional Practice Gaps | 1 | 2017 | 15 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1274 | 0.150 |
Why?
|
| Acetaminophen | 1 | 2018 | 116 | 0.150 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2017 | 32 | 0.150 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 445 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 1248 | 0.150 |
Why?
|
| Influenza A virus | 1 | 2018 | 270 | 0.140 |
Why?
|
| Ketorolac Tromethamine | 1 | 2016 | 2 | 0.140 |
Why?
|
| Middle Aged | 9 | 2022 | 86204 | 0.140 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 106 | 0.140 |
Why?
|
| Pandemics | 5 | 2023 | 1559 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2016 | 190 | 0.130 |
Why?
|
| Cardiology | 1 | 2021 | 530 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 196 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 332 | 0.130 |
Why?
|
| Registries | 1 | 2023 | 2170 | 0.130 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2018 | 211 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 257 | 0.130 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2015 | 30 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 739 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2020 | 691 | 0.130 |
Why?
|
| Drug Utilization | 1 | 2016 | 179 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 245 | 0.120 |
Why?
|
| Potassium Chloride | 1 | 2014 | 55 | 0.120 |
Why?
|
| Leg | 1 | 2015 | 226 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 190 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 1217 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 715 | 0.110 |
Why?
|
| Stroke | 1 | 2021 | 1144 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1537 | 0.110 |
Why?
|
| Medicare | 1 | 2017 | 860 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 674 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 29902 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2016 | 492 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 860 | 0.100 |
Why?
|
| Incidence | 2 | 2021 | 5673 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 1904 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4892 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 2315 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2015 | 1819 | 0.090 |
Why?
|
| Administration, Sublingual | 2 | 2019 | 25 | 0.090 |
Why?
|
| Prevalence | 1 | 2017 | 3260 | 0.080 |
Why?
|
| Age Factors | 1 | 2017 | 5377 | 0.080 |
Why?
|
| Myocardium | 1 | 2014 | 1313 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2022 | 37905 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2021 | 32848 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2403 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 3719 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 45 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 53 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2024 | 225 | 0.060 |
Why?
|
| United States | 2 | 2018 | 15433 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2020 | 2588 | 0.060 |
Why?
|
| Child | 3 | 2023 | 29154 | 0.060 |
Why?
|
| Glycopeptides | 1 | 2022 | 28 | 0.050 |
Why?
|
| Cystatin C | 1 | 2022 | 54 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2024 | 684 | 0.050 |
Why?
|
| Dobutamine | 1 | 2022 | 54 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 131 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2023 | 170 | 0.050 |
Why?
|
| Risk Factors | 2 | 2021 | 17523 | 0.050 |
Why?
|
| Leukocytes | 1 | 2024 | 422 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 5047 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 589 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 151 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 531 | 0.050 |
Why?
|
| Prognosis | 3 | 2023 | 21713 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2022 | 577 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2023 | 431 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 223 | 0.040 |
Why?
|
| Analgesics | 1 | 2022 | 390 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2020 | 105 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2018 | 27 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 53 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2018 | 119 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 989 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2018 | 621 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 694 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 834 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2146 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2018 | 427 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 6682 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 59536 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 1054 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2018 | 925 | 0.020 |
Why?
|
| Aged | 3 | 2022 | 70117 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 4938 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4971 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4320 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2004 | 105 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 249 | 0.010 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2004 | 50 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 12926 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 377 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 706 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 611 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2004 | 256 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2004 | 344 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 995 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 1258 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1487 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 1271 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 4233 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 6089 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 5114 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 11965 | 0.000 |
Why?
|